Wall Street analysts expect that Bio-Path Holdings Inc (NASDAQ:BPTH) will report earnings per share of ($0.20) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Bio-Path’s earnings. Bio-Path posted earnings of ($0.10) per share in the same quarter last year, which suggests a negative year over year growth rate of 100%. The business is expected to issue its next earnings results on Wednesday, March 21st.
According to Zacks, analysts expect that Bio-Path will report full-year earnings of ($0.80) per share for the current financial year. For the next financial year, analysts forecast that the business will post earnings of ($0.90) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Bio-Path.
Several equities analysts have recently weighed in on BPTH shares. cut their target price on Bio-Path from $45.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday, November 15th. HC Wainwright reissued a “buy” rating and set a $15.00 target price (down previously from $45.00) on shares of Bio-Path in a research report on Monday, November 13th. Finally, ValuEngine raised Bio-Path from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. Bio-Path presently has a consensus rating of “Hold” and a consensus target price of $16.67.
Bio-Path (BPTH) traded down $0.02 during trading hours on Wednesday, reaching $1.58. The company’s stock had a trading volume of 78,200 shares, compared to its average volume of 119,960. Bio-Path has a 1-year low of $1.53 and a 1-year high of $10.10. The company has a market cap of $17.92, a P/E ratio of -2.26 and a beta of 3.01.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in BPTH. Renaissance Technologies LLC increased its position in shares of Bio-Path by 64.9% during the 4th quarter. Renaissance Technologies LLC now owns 683,900 shares of the company’s stock valued at $138,000 after purchasing an additional 269,200 shares during the last quarter. Hudson Bay Capital Management LP bought a new position in Bio-Path in the 4th quarter valued at $157,000. Anson Funds Management LP bought a new position in Bio-Path in the 4th quarter valued at $272,000. Sabby Management LLC bought a new position in Bio-Path in the 4th quarter valued at $371,000. Finally, HighTower Advisors LLC grew its position in Bio-Path by 0.3% in the 2nd quarter. HighTower Advisors LLC now owns 1,267,070 shares of the company’s stock valued at $492,000 after acquiring an additional 4,000 shares during the last quarter.
TRADEMARK VIOLATION NOTICE: This story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/19/0-20-earnings-per-share-expected-for-bio-path-holdings-inc-bpth-this-quarter.html.
Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.
Get a free copy of the Zacks research report on Bio-Path (BPTH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.